Q-omics provides the consensus-scored RBMY2TP profile across patient tissues and cancer cell-line models. RBMY2TP expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in THYM. Additionally, RBMY2TP RNA expression shows 4,397 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, and STAD as cancer lineages where RBMY2TP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.